WorldCat Identities

Henique, Hélène (1985-....).

Overview
Works: 5 works in 6 publications in 2 languages and 9 library holdings
Roles: Opponent, Author
Publication Timeline
.
Most widely held works by Hélène Henique
Evaluation de l'efficacité et de la tolérance du rituximab chez les patients atteints d'une pneumopathie d'hypersensibilité chronique (PHS) : étude observationnelle rétrospective by Marion Ferreira( )

2 editions published in 2020 in French and held by 3 WorldCat member libraries worldwide

Introduction : au sein des PHS, il existe des formes chroniques qui peuvent évoluer vers une fibrose pulmonaire scannographique avec parfois des aspects histologiques de pneumopathie interstitielle non spécifique ou de pneumopathie interstitielle commune. L'éviction antigénique, traitement primordial et souvent seul efficace, n'empêche pas certaines formes fibrosantes d'évoluer pour leur propre compte. Il n'existe aucune recommandation concernant le traitement des patients s'aggravant sur le plan respiratoire malgré une éviction antigénique. Il semblerait que le rituximab, par la déplétion des lymphocytes B, puisse apporter un bénéfice chez les patients avec une forme fibrosante de PHS. L'objectif de cette étude était d'évaluer l'efficacité du rituximab sur la fonction respiratoire de patients atteints de PHS fibrosantes. Matériels et méthodes : cette étude rétrospective multicentrique française a été menée de novembre 2018 à juillet 2019. L'évolution de la capacité vitale forcée (CVF) à 6 mois de l'introduction du rituximab a été mesurée chez 23 patients atteints de PHS fibrosantes. Résultats : Vingt-trois patients, dont 12 femmes, d'âge médian de 63 ans ont été inclus au sein de 7 centres hospitaliers universitaires français. Alors que la CVF baissait significativement dans les 6 mois précédant l'introduction du rituximab (63% [35;112%] à M-6 versus 56% [29;102%] à M0 ; p<0,0001), la CVF à 6 mois de l'introduction du rituximab (61% [38;99%]) n'était pas significativement différente de celle de M0. Alors que tous les patients présentaient une baisse de leur CVF entre M-6 et M0, sept patients (30%) présentaient une amélioration ou une stabilité de leur CVF à M+6. Le déclin de la CVF entre M0 et M+6 (-3% [-38;+19%]) était significativement moins important que celui entre M-6 et M0 (-8% [-21;0%]) (p = 0,0002). Entre M0 (37% [16;73%]) et M+6 (42% [15;70%]), la capacité de transfert du monoxyde de carbone (DLCO) médiane est restée stable (p=0,12). Six des 9 patients (67%) pour lesquels une valeur de DLCO était disponible à M+6 amélioraient leur DLCO. La dose médiane de corticoïdes entre M-6 et M0 est restée stable (15mg [0;40mg] versus 20mg [10;60mg] ; p=0,75) tandis qu'elle a diminué significativement entre M0 et M+6 (12mg [0;30mg] ; p=0,008). Sept patients (30%) ont présenté une infection lors de leur traitement par rituximab, dont 6 étaient des infections respiratoires sans identification microbiologique. Un patient (4%) est décédé de son infection respiratoire. Conclusion : Le rituximab pourrait être une alternative thérapeutique chez les patients présentant une PHS chronique fibrosante résistante à une éviction antigénique bien menée et/ou à une corticothérapie. Son utilisation semble s'accompagner d'une bonne tolérance en plus d'une stabilisation ou d'une amélioration de la fonction respiratoire de certains patients
Evaluation de la prise en charge et du pronostic du syndrome RSP3PE by Hélène Henique( Book )

1 edition published in 2015 in French and held by 2 WorldCat member libraries worldwide

Introduction. RS3PE syndrome (Remitting Seronegative Symmetrical Synovitis with Pitting Edema) is a non erosive, seronegative polyarthritis with edema of the extremities, occuring in the elderly. Its prognosis is usually favorable with steroids but RS3PE can be also a paraneoplastic manifestation of an underlying malignancy. Nowadays, the management of patients is not consensual. In this context, the aim of our study was to evaluate the treatment and prognosis of RS3PE. Patients and methods. We performed a retrospective observational study in internal medicine and rheumatology units of the Centre-Ouest region. Clinical, biological, and outcome data were collected. A descriptive statistical analysis, Wilcoxon and Student t tests were used. Results (mean ± SD). Twenty patients were included (12 men and 8 women). The age at diagnosis was 74 ± 9 years. The initial CRP was 96.3 ± 57.2 mg/l [11-197]. Additional tests were performed in all patients to exclude underlying malignancies. The body CT was the most frequently done exam. Two cancers (10% of cases) were found with a median 9 months. 80% of patients received oral corticosteroids average dosage of 32 mg/day [10-80] of prednisone equivalent. Five patients, all male, have relapsed within a median of 12 months. They had an initial inflammatory syndrome statistically higher than the other patients (139 vs 82 mg/L, p = 0.05). The second-line treatment was methotrexate for 4 of these patients. Discussion / Conclusion. Our study shows that the detection of underlying tumors was quite homogeneous. However, the therapeutic management is various in duration and dosage. There is a significant risk of relapse. Methotrexate appears to be an interesting second-line treatment. These results must be confirmed by a larger study
Linear Cutaneous Erythema in a Patient With Amyotrophic Lateral Sclerosis( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Evaluation de la prise en charge et du pronostic du syndrome RS3PE by Hélène Henique( )

1 edition published in 2015 in French and held by 1 WorldCat member library worldwide

Introduction. RS3PE syndrome (Remitting Seronegative Symmetrical Synovitis with Pitting Edema) is a non erosive, seronegative polyarthritis with edema of the extremities, occuring in the elderly. Its prognosis is usually favorable with steroids but RS3PE can be also a paraneoplastic manifestation of an underlying malignancy. Nowadays, the management of patients is not consensual. In this context, the aim of our study was to evaluate the treatment and prognosis of RS3PE. Patients and methods. We performed a retrospective observational study in internal medicine and rheumatology units of the Centre-Ouest region. Clinical, biological, and outcome data were collected. A descriptive statistical analysis, Wilcoxon and Student t tests were used. Results (mean ± SD). Twenty patients were included (12 men and 8 women). The age at diagnosis was 74 ± 9 years. The initial CRP was 96.3 ± 57.2 mg/l [11-197]. Additional tests were performed in all patients to exclude underlying malignancies. The body CT was the most frequently done exam. Two cancers (10% of cases) were found with a median 9 months. 80% of patients received oral corticosteroids average dosage of 32 mg/day [10-80] of prednisone equivalent. Five patients, all male, have relapsed within a median of 12 months. They had an initial inflammatory syndrome statistically higher than the other patients (139 vs 82 mg/L, p = 0.05). The second-line treatment was methotrexate for 4 of these patients. Discussion / Conclusion. Our study shows that the detection of underlying tumors was quite homogeneous. However, the therapeutic management is various in duration and dosage. There is a significant risk of relapse. Methotrexate appears to be an interesting second-line treatment. These results must be confirmed by a larger study
 
Audience Level
0
Audience Level
1
  General Special  
Audience level: 0.94 (from 0.88 for Linear Cut ... to 0.95 for Evaluation ...)

Languages